Urology is experiencing significant market transformation. Multisite platform formation and "supergroup" consolidation have accelerated as private equity and strategic investors target urology's robust outpatient volumes, diverse ancillary service mix, and the ability to scale care in lower-cost settings. Practices are expanding into ambulatory surgery centers (ASCs), advanced imaging and laboratory integrations, radiation therapy centers, in-office dispensaries, lithotripsy centers, and benign prostatic hyperplasia (BPH) device procedures. Private equity-backed urology platforms have grown substantially in recent years, with management services organizations (MSOs) acquiring large independent and mid-sized groups.
Baker Donelson's Health Care Transactions team brings deep experience and industry perspective to every engagement. We structure and negotiate practice sales, recapitalizations, platform acquisitions, joint ventures, and partnerships with private equity sponsors, strategic platforms, and health systems.
We assist with structuring ASC ownership arrangements, anesthesia and device supply contracts, radiation therapy affiliations, pathology and dispensary ventures, and diagnostic imaging arrangements. Our team addresses licensing rules, Stark Law and Anti-Kickback compliance, fee-splitting, and state corporate practice of medicine (CPOM) constraints.
With a proven track record in urology transactions and ancillary service development, Baker Donelson delivers the legal insight and operational strategy needed for practices to achieve strategic growth, clinical excellence, and lasting value.